Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
NCT00326326
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
84
Enrollment
INDUSTRY
Sponsor class
Conditions
Dyslipidemia
Interventions
DRUG:
CP-778,875
Sponsor
Pfizer